Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indacaterol/Glycopyrronium and changes in dyspnea, lung function, and physical activity in COPD
jRCTs061180012Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of indacaterol + glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Primary endpoint: Change in physical activity over 12 weeks. Started Apr 2017; status: completed.
02
Drugs
indacaterol + glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCTs061180012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180012.